Freedom of Information request on product licenses for OxyContin 5mg, 20mg, 40mg and 80mg prolonged-release tablets (FOI 21-665)
Published 13 August 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-21-june-2021/freedom-of-information-request-on-product-licenses-for-oxycontin-5mg-20mg-40mg-and-80mg-prolonged-release-tablets-foi-21-665
21st June 2021 FOI 21/665
Dear
Thank you for your email.
Please see the information below for each product licence:
PL16950/0097 OxyContin 5 mg prolonged-release tablets – This was granted by a national application on 05 March 1999
PL16950/0100 OxyContin 20 mg prolonged-release tablets – This was granted by a national application on 05 March 1999
PL16950/0139 OxyContin 40 mg prolonged-release tablets – This was granted by a national application on 07 September 2010
PL16950/0141 OxyContin 80 mg prolonged-release tablets – This was granted by a national application on 07 September 2010
If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review will be carried out by a senior member of the Agency who was not involved with the original decision.
If you have a query about the information provided, please reply to this email
If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk
Due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices
Please remember to quote the reference number above in any future communications.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner’s Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF
Yours sincerely
MHRA Customer Service Centre
Medicines and Healthcare products Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU